Received Sep 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
no adverse event; inappropriate schedule of vaccine administration; in May 2024, I received my first dose of Gardasil 4. Due to personal circumstances, I was unable to follow the recommended schedule. On August 26, 2025, I received a dose of Gardasil 9; This spontaneous report was received from a consumer patient of unknown age and gender and refers to themself. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. In May 2024, the patient was vaccinated with the first dose of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL), Suspension for injection, dose number 1, (indication, expiration date, and lot # were not reported). Due to personal circumstances, the patient was unable to follow the recommended schedule. On 26-Aug-2025, the patient received second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (interchange of vaccine products; inappropriate schedule of vaccine administration), Suspension for injection, dose number 2, (indication, expiration date, and lot # were not reported). The patient asked for advice how to proceed. Should one additional dose be received in 6 months to complete the series, or, since the initial Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL) dose was more than one year ago, should the patient restart a full 3-dose Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) schedule beginning from today? No adverse event was reported.